Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

Kanza, Eric M.; Nyathirombo, Amos; Larbelee, Jemmah P.; Opoku, Nicholas O.; Bakajika, Didier K.; Howard, Hayford M.; Mambandu, Germain L.; Nigo, Maurice M.; Wonyarossi, Deogratias Ucima; Ngave, Françoise; Kennedy, Kambale Kasonia; Kataliko, Kambale; Bolay, Kpehe M.; Attah, Simon K.; Olipoh, George; Asare, Sampson; Mumbere, Mupenzi; Vaillant, Michel; Halleux, Christine M.; Kuesel, Annette C.

doi:10.1186/s13071-023-06087-3

Table 4 Number (%) of participants by mfAC category pre-treatment and on Day 4 and Month 1, 6, 12 and 18 by intensity of infection

From: Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

IoI	Moxidectin													Ivermectin
	All	0 mfAC		1–5 mfAC		6–10 mfAC		11–20 mfAC		21–40 mfAC		> 40 mfAC		All	0 mfAC		1–5 mfAC		6–10 mfAC		11–20 mfAC		21–40 mfAC		> 40 mfAC
	N	n	%	N	%	n	%	n	%	n	%	n	%	N	N	%	n	%	n	%	n	%	n	%	n	%
	Pre-treatment
< 20	279	197	70.6	27	9.7	14	5.0	21	7.5	18	6.5	2	0.7	148	103	69.6	16	10.8	5	3.4	12	8.1	6	4.1	6	4.1
20- < 50	454	299	65.9	77	17.0	25	5.5	25	5.5	20	4.4	8	1.8	181	103	56.9	43	23.8	12	6.6	15	8.3	6	3.3	2	1.1
≥ 50	240	100	41.7	79	32.9	20	8.3	21	8.8	14	5.8	6	2.5	161	83	51.6	37	23.0	12	7.5	18	11.2	6	3.7	5	3.1
All	973	596	61.3	183	18.8	59	6.1	67	6.9	52	5.3	16	1.6	490	289	59.0	96	19.6	29	5.9	45	9.2	18	3.7	13	2.7
	Day 4
< 20	279	170	60.9	59	21.1	17	6.1	21	7.5	8	2.9	4	1.4	148	98	66.2	18	12.2	10	6.8	8	5.4	10	6.8	4	2.7
20- < 50	454	259	57.0	113	24.9	30	6.6	33	7.3	12	2.6	7	1.5	181	108	59.7	39	21.5	13	7.2	13	7.2	7	3.9	1	0.6
≥ 50	240	105	43.8	68	28.3	25	10.4	19	7.9	12	5.0	11	4.6	161	59	36.6	48	29.8	19	11.8	13	8.1	12	7.5	10	6.2
All	973	534	54.9	240	24.7	72	7.4	73	7.5	32	3.3	22	2.3	490	265	54.1	105	21.4	42	8.6	34	6.9	29	5.9	15	3.1
	Month 1
< 20	278	233	83.8	39	14.0	2	0.7	2	0.7	2	0.7			148	120	81.1	18	12.2	4	2.7	2	1.4	4	2.7
20- < 50	450	332	73.8	86	19.1	16	3.6	13	2.9	2	0.4	1	0.2	181	136	75.1	39	21.5	4	2.2	1	0.6	1	0.6
≥ 50	239	126	52.7	77	32.2	9	3.8	11	4.6	10	4.2	6	2.5	159	91	57.2	38	23.9	12	7.5	6	3.8	6	3.8	6	3.8
All	967	691	71.5	202	20.9	27	2.8	26	2.7	14	1.4	7	0.7	488	347	71.1	95	19.5	20	4.1	9	1.8	11	2.3	6	1.2
	Month 6
< 20	273	269	98.5	4	1.5									148	144	97.3	3	2.0			1	0.7
20- < 50	446	424	95.1	20	4.5	2	0.4							179	170	95.0	9	5.0
≥ 50	237	213	89.9	17	7.2	3	1.3	4	1.7					160	151	94.4	8	5.0							1	0.6
All	956	906	94.8	41	4.3	5	0.5	4	0.4					487	465	95.5	20	4.1			1	0.2			1	0.2
	Month 12
< 20	268	265	98.9	2	0.7	1	0.4							146	140	95.9	4	2.7	1	0.7	1	0.7
20- < 50	437	426	97.5	9	2.1	1	0.2			1	0.2			175	172	98.3	3	1.7
≥ 50	236	232	98.3	3	1.3			1	0.4					155	143	92.3	10	6.5	1	0.6					1	0.6
All	941	923	98.1	14	1.5	2	0.2	1	0.1	1	0.1			476	455	95.6	17	3.6	2	0.4	1	0.2			1	0.2
	Month 18
< 20	224	223	99.6	1	0.4									115	111	96.5	2	1.7	1	0.9	1	0.9
20- < 50	334	327	97.9	6	1.8	1	0.3							138	137	99.3	1	0.7
≥ 50	200	198	99.0	2	1.0		0.0							129	118	91.5	9	7.0	1	0.8					1	0.8
All	758	748	98.7	9	1.2	1	0.1							382	366	95.8	12	3.1	2	0.5	1	0.3			1	0.3

PreTx pre-treatment, IoI pre-treatment skin microfilariae density (microfilariae/mg skin)

Back to article page

ISSN: 1756-3305

Contact us

Submission enquiries: journalsubmissions@springernature.com

Parasites & Vectors

Contact us